Phosphodiesterase-4 isoforms: intracellular targeting, regulation and potential therapeutic targets

COPD kills 3 million people each year, and the drugs that could stop the lung inflammation driving it also cause severe nausea and vomiting in most patients. The problem is that current medicines block all versions of an enzyme called PDE4, but only one specific subtype drives inflammation in the lungs. The rest are needed elsewhere in the body—blocking them triggers the sickness. This research targets that single rogue subtype by exploiting a discovery: each PDE4 variant carries a unique molecular "postcode" that directs it to the correct location inside a cell. The team aims to find molecules that scramble that postcode, disabling only the harmful enzyme without touching the others. If successful, this would produce a new class of COPD treatments that reduce inflammation without the side effects that currently force patients to stop taking them. Because the approach targets a fundamental mechanism of enzyme localisation, it could also apply to other inflammatory diseases where specific PDE4 subtypes play a role. This is fundamental science with a clear therapeutic target—understanding how cells sort their enzymes could unlock drugs for conditions where broad inhibition has proven too toxic to use.